Quantcast
Last updated on April 18, 2014 at 6:03 EDT

Latest Genomic Health Inc. Stories

2013-11-22 08:23:32

BMC Genomics Publishes Analytical Validation Showing Oncotype DX Overcomes the Challenges of Testing from Very Small Prostate Cancer Needle Biopsy Sample REDWOOD CITY, Calif., Nov. 22, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that BMC Genomics published positive results from its analytical validation study demonstrating that the Oncotype DX(®) prostate cancer test is a reliable assay, even with very limited RNA inputs, which enables successful...

2013-11-13 08:26:15

Journal of Clinical Oncology Publishes Positive Results from Third Successful Validation in Stage II Colon Cancer, First Validation in Patients with Stage III Disease REDWOOD CITY, Calif., Nov. 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) has published positive results from a large, independent validation study of the Oncotype DX(®) colon cancer test in patients from the National Surgical Adjuvant Breast and...

2013-11-05 16:26:30

Product Revenue Increased 13% Compared to Prior Year REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Product revenue was $65.7 million in the third quarter of 2013, compared with $58.4 million for the third quarter of 2012, an increase of 13 percent. Total revenue for the third quarter of 2013...

2013-11-05 08:34:44

Current Medical Research & Opinion Publishes Positive Decision Impact Study Demonstrating Significant Impact on Colon Cancer Treatment Recommendations REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Current Medical Research & Opinion (CMRO) published positive results from the Partnership for Health Analytic Research (PHAR) clinical utility analysis of the Oncotype DX(®) colon cancer test, demonstrating that use of the...

2013-10-29 08:33:03

REDWOOD CITY, Calif., Oct. 29, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 5 at 4:30 p.m. Eastern Time to discuss its third quarter 2013 financial results. The call and webcast will follow the release of the third quarter financial results after market close. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Conference Call DetailsTo access the live conference...

2013-10-01 04:22:41

Four Studies Presented at the European Cancer Congress, Following NICE's Recommendation for Using Oncotype DX Test to Guide Chemotherapy Decisions in Early-stage Breast Cancer Patients AMSTERDAM and REDWOOD CITY, Calif., Oct. 1, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from four studies highlighting the value of its Oncotype DX(®) tests for optimizing treatment for patients with breast and colon cancer. Three new decision impact studies - including...

2013-09-25 08:28:47

NICE's Recommendation of Oncotype DX® Test is an Important Milestone in Delivering Personalized Medicine to More UK Patients REDWOOD CITY, Calif., Sept. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its final guidance recommending Oncotype DX(®) as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients...

2013-08-22 08:26:56

The 13th St. Gallen International Expert Consensus Panel Report Emphasizes Oncotype DX's Unsurpassed Clinical Validation Supporting Greater Use and Reimbursement of the Test Worldwide GENEVA and REDWOOD CITY, Calif., Aug. 22, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the 13(th) St. Gallen International Breast Cancer Conference Expert Panel, for the second time, recognized the Oncotype DX(®) breast cancer test for its ability to provide not only...

2013-08-07 16:28:28

REDWOOD CITY, Calif., Aug. 7, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the Canaccord Genuity 33(rd) Annual Growth Conference in Boston on Wednesday, August 14 at 2:00 p.m. Eastern Time (ET). (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at...

2013-07-31 16:28:04

Product Revenue Increased 11% Compared to Prior Year REDWOOD CITY, Calif., July 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Product revenue was $63.7 million in the second quarter of 2013, compared with $57.2 million for the second quarter of 2012, an increase of 11 percent. Total revenue for the second...